<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741286</url>
  </required_header>
  <id_info>
    <org_study_id>ECLIPse</org_study_id>
    <nct_id>NCT00741286</nct_id>
  </id_info>
  <brief_title>Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler</brief_title>
  <acronym>ECLIPse</acronym>
  <official_title>Study for the Multi-Center Placebo-Controlled Double-Blind Clinical Trial for the Evaluation of the Effect of Cilostazol on Pulsatility Index of Transcranial Doppler in the Acute Lacunar Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE:

        -  Elevation in pulsatility indices (PIs), measured by transcranial Doppler (TCD), has been
           postulated to reflect downstream increased vascular resistance caused by small-vessel
           disease (SVD).

        -  Small arterial vessels are a significant determinant of vascular resistance and PIs are
           elevated when SVD is present in the intracranial circulation.

        -  Cilostazol, a phosphodiesterase III inhibitor, has other non-antiplatelet effects, such
           as vasodilation and neuroprotective effect. It has been shown to be effective in the
           secondary prevention of stroke especially in the SVD and it may be related to the other
           non-antiplatelet effects of cilostazol.

      OBJECTIVES:

        -  In this study, we aim to investigate whether cilostazol affects the changes of PIs in
           patients with acute lacunar infarction using serial TCDs.

        -  Our hypothesis is that cilostazol has other non-antiplatelet effects such as
           vasodilation effect and may decrease the vascular resistance in patients with acute
           lacunar infarction. Hence, cilostazol will decrease the PIs in patients with acute
           lacunar infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENTS:

        -  Cilostazol is an agent inhibiting platelet aggregation.

        -  A matching placebo of cilostazol is an inactive substance that looks similar to the
           active cilostazol tablet.

      TREATMENT PLAN:

        -  There will be two treatment groups; one will receive cilostazol 200mg (100mg twice per
           day), the second matching placebo of cilostazol.

        -  These study drugs will be administered on top of aspirin (100mg) systematically
           prescribed to such patients

      PRIMARY ENDPOINT:

        -  The changes of PI between the baseline and 14 and 90 days follow-up study.

      STUDY EXECUTION:

        -  Two hundred sixty patients, presenting with first ever lacunar infarction within 7 days
           after the onset of symptoms will be recruited within two years.

        -  Patients will be followed up during the three months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study</measure>
    <time_frame>14 days and 90 days from the baseline TCD study</time_frame>
    <description>The PI is designed to measure vascular resistance and characterizes the shape of the spectral waveform. For the study, the mean, systolic, and diastolic flow velocities were measured using TCD. Gosling's PI was determined as the difference between the peak systolic and end-diastolic velocities divided by the mean flow velocity in each artery.The changes of MCA and BA PIs at 14 and 90 days from the baseline TCD study was calculated for the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With First Recurrent Stroke of Any Type</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Asprin (100mg) plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Asprin (100mg) plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asprin (100mg) plus cilostazol (200mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Asprin (100mg) plus cilostazol (200mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Asprin (100mg) plus placebo</description>
    <arm_group_label>Asprin (100mg) plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>Aspirin (100mg) plus cilostazol (200mg)</description>
    <arm_group_label>Asprin (100mg) plus cilostazol (200mg)</arm_group_label>
    <other_name>Pletaal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with first ever lacunar infarction within 7 days after the onset of symptoms

          -  Age: more than 45 years of age

        Exclusion Criteria:

          -  Patients with any contraindications to the treatment with antiplatelet therapy

          -  Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation,
             atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left
             ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular
             segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse,
             mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis,
             congestive heart failure, recent myocardial infarction (within 4 weeks)

          -  Bleeding diathesis

          -  Chronic liver disease (ALT &gt; 100 or AST &gt; 100) or chronic renal disease (creatinine &gt;
             3.0mg/dl)

          -  Anemia (hemoglobin &lt; 10mg/dl) or thrombocytopenia (platelet count less than
             100,000/mm3)

          -  Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting
             arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated
             angiopathy, and other vasculitis.

          -  Pregnant or lactating patients

          -  Patients with hyperthyroidism or COPD

          -  Patients with current anticoagulation or antiplatelet therapy

          -  Patients with poor temporal window in transcranial Doppler
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hyeon Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanggye Paik Hospital, Inje University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanbon Medical Center</name>
      <address>
        <city>Gunpo</city>
        <zip>435-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <zip>411-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang CHA Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National medical center</name>
      <address>
        <city>Seoul</city>
        <zip>100-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yongdong Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <results_first_submitted>August 3, 2010</results_first_submitted>
  <results_first_submitted_qc>August 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2011</results_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jae Hyeon Park, MD, PhD</name_title>
    <organization>Sanggye Paik Hospital, Inje University College of Medicine</organization>
  </responsible_party>
  <keyword>Cerebral infarction</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Transcranial Doppler</keyword>
  <keyword>Pulsatile Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Stroke, Lacunar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>ECLIPse was designed as a multicenter, randomized, double-blind, placebo-controlled trial. Between November 2006 and October 2008, 203 patients were consecutively enrolled from eight tertiary-care hospitals.</recruitment_details>
      <pre_assignment_details>A total of 513 patients who had experienced their first classic lacunar syndromes were screened for study enrollment, of which 101 (19.7% of the screened population) refused to participate in the study. Seventy-four patients (14.4%) were not eligible for the trial, and 135 (26.3%) were excluded by the exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Asprin Plus Placebo</title>
          <description>Placebo twice a day on top of aspirin 100mg a day</description>
        </group>
        <group group_id="P2">
          <title>Asprin Plus Cilostazol</title>
          <description>Cilostazol (100mg) twice a day on top of aspirin 100mg a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Primary Outcome</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asprin Plus Placebo</title>
          <description>Placebo twice a day on top of aspirin 100mg a day</description>
        </group>
        <group group_id="B2">
          <title>Asprin Plus Cilostazol</title>
          <description>Cilostazol (100mg) twice a day on top of aspirin 100mg a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.48" spread="9.92"/>
                    <measurement group_id="B2" value="64.63" spread="9.07"/>
                    <measurement group_id="B3" value="65.06" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study</title>
        <description>The PI is designed to measure vascular resistance and characterizes the shape of the spectral waveform. For the study, the mean, systolic, and diastolic flow velocities were measured using TCD. Gosling’s PI was determined as the difference between the peak systolic and end-diastolic velocities divided by the mean flow velocity in each artery.The changes of MCA and BA PIs at 14 and 90 days from the baseline TCD study was calculated for the study.</description>
        <time_frame>14 days and 90 days from the baseline TCD study</time_frame>
        <population>Of the 203 patients included in the intention-to-treat analysis, 164 were included in the per-protocol analysis of the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Asprin Plus Placebo</title>
            <description>Placebo twice a day on top of aspirin 100mg a day</description>
          </group>
          <group group_id="O2">
            <title>Asprin Plus Cilostazol</title>
            <description>Cilostazol (100mg) twice a day on top of aspirin 100mg a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study</title>
          <description>The PI is designed to measure vascular resistance and characterizes the shape of the spectral waveform. For the study, the mean, systolic, and diastolic flow velocities were measured using TCD. Gosling’s PI was determined as the difference between the peak systolic and end-diastolic velocities divided by the mean flow velocity in each artery.The changes of MCA and BA PIs at 14 and 90 days from the baseline TCD study was calculated for the study.</description>
          <population>Of the 203 patients included in the intention-to-treat analysis, 164 were included in the per-protocol analysis of the primary outcome.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes of PI in Right MCA (14 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.13"/>
                    <measurement group_id="O2" value="0.08" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of PI in Right MCA (90 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.13"/>
                    <measurement group_id="O2" value="0.14" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of PI in Left MCA (14 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.13"/>
                    <measurement group_id="O2" value="0.1" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of PI in Left MCA (90 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.13"/>
                    <measurement group_id="O2" value="0.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of PI in BA (14 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.14"/>
                    <measurement group_id="O2" value="0.09" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes of PI in BA (90 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.18"/>
                    <measurement group_id="O2" value="0.18" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model for a repeated measures covariance pattern model with unstructured covariances within subjects was used. Two fixed effects were included: 1 between-subjects treatment effect (group: cilostazol, control) and 1 within-subject time effect (time: baseline, 14 days, 90 days). A possible difference in treatment across 14- and 90-day follow-up was analyzed by time x treatment interactions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To determine between-group differences of changes in the PIs at 14 and 90 days from the baseline study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With First Recurrent Stroke of Any Type</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Asprin Plus Placebo</title>
            <description>Placebo twice a day on top of aspirin 100mg a day</description>
          </group>
          <group group_id="O2">
            <title>Asprin Plus Cilostazol</title>
            <description>Cilostazol (100mg) twice a day on top of aspirin 100mg a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Recurrent Stroke of Any Type</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Asprin Plus Placebo</title>
          <description>Placebo twice a day on top of aspirin 100mg a day</description>
        </group>
        <group group_id="E2">
          <title>Asprin Plus Cilostazol</title>
          <description>Cilostazol (100mg) twice a day on top of aspirin 100mg a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sang Won Han</name_or_title>
      <organization>Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine</organization>
      <phone>82-2-950-8864</phone>
      <email>swhan@paik.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

